Decitabine, Vaccine Therapy, and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer

Inclusion Criteria: * Subjects with relapsed epithelial ovarian cancer (including fallopian tube and primary peritoneal cancer) who will receive liposomal doxorubicin as salvage therapy for recurrent disease * Patients may have received up to four previous lines of chemotherapy * The relapse may be defined by an increase in CA125; there may or may not be either measurable or symptomatic disease * Any human leukocyte antigen (HLA) type * No requirement for tumor expression of NY-ESO-1 * Karnofsky performance status of \> 70% * Not previously treated with doxorubicin * Life expectancy \>= 6 months * Hematology and biochemistry laboratory results within the limits normally expected for the patient population, without evidence of major organ failure * No immunodeficiency * Have been informed of other treatment options * Able and willing to give valid written informed consent * Neutrophil count \>= 1.5 x 10\^9 * Platelet count \>= 100 x 10\^9 * Serum creatinine =\< 2.1 mg/dL * Serum bilirubin =\< 2 mg/dL * Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =\< 2.6 x upper limit of normal (ULN) (normal ranges: AST 15-46 U/L; ALT 11-66 U/L) Exclusion Criteria: * Metastatic disease to the central nervous system for which other therapeutic options, including radiotherapy, may be available * Other serious illnesses (e.g., serious infections requiring antibiotics, bleeding disorders) * History of autoimmune disease (e.g., thyroiditis, lupus) except vitiligo * Concomitant systemic treatment with corticosteroids, anti-histamine or non-steroidal anti-inflammatory drugs; specific CQX-2 inhibitors are permitted * Chemotherapy, radiation therapy, or immunotherapy within 4 weeks prior to first dosing of study agent (6 weeks for nitrosoureas) * Known human immunodeficiency virus (HIV) positivity * Known allergy or history of life threatening reaction to GM-CSF * Myocardial infarction, angina, congestive heart failure, cardiomyopathy, stroke or transient ischemic attack, chest pain or shortness of breath with activity, or other heart conditions being treated by a doctor * Participation in any other clinical trial involving another investigational agent within 4 weeks prior to first dosing of study agent * Mental impairment that may compromise the ability to give informed consent and comply with the requirements of the study * Lack of availability of a patient for immunological and clinical follow-up assessment